Rethinking Fertility Care: Dr. Zaher Merhi’s AI-Driven Approach
When Dr. Zaher Merhi launched his fertility practice, he initially adhered to the conventional protocols used by most reproductive endocrinologists. This meant employing high-dose stimulation medications, conducting extensive preliminary testing over several weeks before treatment commencement, and applying standardized protocols designed around average patient profiles. While this approach ensured consistency, it often overlooked the individual nuances of each patient’s reproductive health.
Despite his expertise, Dr. Merhi frequently encountered a frustrating pattern. Many women in their early 30s, who were otherwise healthy and motivated with good ovarian reserves, found themselves caught in a system that consumed significant time and financial resources without guaranteeing successful outcomes. Patients often endured four to eight weeks of intake testing before receiving their first injection, spent thousands of dollars on medications—much of which went unused—and experienced embryo assessments based on subjective visual inspections by technicians. The result? Exhaustion, high costs often around $20,000, and outcomes that did not match their efforts or hopes.
The Problem With “One Size Fits All” Medicine
Fertility treatment, much like many other areas of medicine, has traditionally been structured around averages. Clinical protocols rely heavily on population-level data, which are then uniformly applied to all patients. However, this average patient is a theoretical construct rather than a reality. Each woman’s hormonal profile, ovarian reserve, and medication response are unique, yet most clinics initiate treatment with the same stimulation doses, make adjustments based on rudimentary blood markers, and select embryos through subjective visual assessments.
The pharmaceutical industry’s incentives further complicate this landscape. Increased medication usage translates directly into higher revenues, while longer treatment timelines mean more monitoring visits and billable procedures. Unfortunately, these incentives are often misaligned with the best interests of patients.
Dr. Merhi was determined to break away from this model.
What AI Actually Changes (Not the Hype, The Reality)
In 2025, Dr. Merhi began integrating artificial intelligence tools into his fertility practice—not as a buzzword, but as targeted solutions aimed at closing critical gaps in care. He emphasizes the difference between AI hype and its practical, clinical applications.
Key AI-driven innovations implemented at his clinic include:
- Medication dosing algorithms: By inputting a patient’s baseline hormone levels and ovarian reserve markers into predictive models, Dr. Merhi personalizes starting doses of stimulation medication. This tailored approach has reduced medication waste at his clinic by over 70%, ensuring patients receive neither too much nor too little medication.
- Continuous embryo monitoring: The EmbryoScope system maintains an uninterrupted incubation environment while capturing images of embryos every ten minutes. An AI model developed by Aurea analyzes thousands of developmental parameters to assign viability scores, replacing subjective technician observations with data-driven assessments trained on hundreds of thousands of embryo development sequences.
- AI-assisted sperm selection: Using advanced computer vision, Aurea evaluates sperm morphology with precision beyond human capability. This innovation particularly benefits couples facing male-factor infertility, transforming the decision-making process in intracytoplasmic sperm injection (ICSI) procedures.
Importantly, AI serves as an augmentative tool rather than a replacement for clinical judgment. Dr. Merhi continues to make every final decision, now armed with richer, faster, and more precise information.
The Business Case Is the Patient Case
The benefits of a more efficient clinical model extend beyond improved patient outcomes to fundamentally transform the economics of fertility care. Lower medication waste—from 35% to under 10%—means patients spend less on costly drugs. Streamlining the treatment timeline from consultation to egg retrieval to roughly two weeks reduces the financial and emotional burden of prolonged care. More accurate embryo selection leads to fewer transfer attempts, enhancing success rates and cost-effectiveness.
Unlike traditional fertility clinics that profit from complexity and extended treatment cycles, Dr. Merhi found that simplifying processes and relying on objective data actually strengthens the business model. This approach challenges entrenched industry assumptions about what constitutes effective and profitable care.
His clinic, Aurea Fertility Center, is specifically designed for women under 40 with good ovarian reserve—the demographic most likely to benefit from AI-optimized, streamlined protocols. For more complex cases such as diminished ovarian reserve or advanced maternal age, Aurea’s sister clinic offers tailored care. This strategic focus underscores the importance of knowing one’s patient base to deliver truly effective treatment.
What Entrepreneurs Can Learn From Fertility Medicine
Dr. Merhi reflects on why healthcare, despite its potential gains from efficiency, has been slow to adopt innovations commonplace in other industries. Regulatory caution plays a role and is often warranted, but institutional inertia and a liability-averse culture also slow progress. Many healthcare providers continue traditional practices simply because “that’s how it’s always been done.”
True disruption in healthcare requires acknowledging where subjective human judgment has masqueraded as evidence-based medicine and replacing it with transparent, data-driven solutions.
From his experience, Dr. Merhi distills three lessons that resonate beyond fertility care:
- Efficiency and quality are not mutually exclusive. Reducing medication doses, testing steps, and treatment timelines does not mean compromising outcomes. Eliminating waste clarifies the signal from the noise, improving results.
- Know your patient or customer with specificity. Generic protocols address generic needs but fail to excel. Designing a clinic around a distinct patient profile sharpens every aspect—from protocols to pricing to communication and technology.
- Lead with outcomes, not technology. Patients care about results, not the technical details behind AI models. Explaining how AI improves embryo selection rather than the mechanics of the algorithm fosters trust and understanding. Entrepreneurs introducing new technologies in conservative markets often err by focusing too much on the “what” before the “why.”
What He Still Doesn’t Know
Dr. Merhi acknowledges the limitations and evolving nature of AI in reproductive medicine. Though current models are trained on extensive datasets, these datasets carry inherent biases and gaps. The tools available today will likely seem rudimentary within a decade.
Moreover, the scalability of his AI-driven clinic model remains uncertain. Medicine is fundamentally a human endeavor—trust, empathy, and presence during vulnerable moments cannot be digitized. Balancing efficiency with intimacy, especially at scale, remains a challenge.
What remains clear to Dr. Merhi is that the traditional fertility care model was inadequate for many patients. It was costly, time-consuming, and often relied on gut decisions where data could have guided better outcomes. Taking the risk to innovate has been worthwhile for both his patients and his practice.
Dr. Zaher Merhi is a reproductive endocrinologist and founder of Aurea Fertility. He has been featured in Forbes, The New York Times, and USA Today for his pioneering work integrating AI into reproductive medicine. Aurea Fertility serves patients nationwide and internationally via telemedicine at aureafertility.com.
For more information, please visit Here.
